Otonomy (OTIC) – Company Press Releases
-
Otonomy Announces Change in Stock Exchange Listing
-
Otonomy Provides Corporate Update
-
Otonomy Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses in Patients with Hearing Loss
-
Otonomy Reports Results from Phase 2 Clinical Trial of OTO-313 in Patients with Tinnitus
-
Otonomy Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Otonomy to Report Second Quarter 2022 Financial Results and Provide Corporate Update
-
Otonomy to Participate in the H.C. Wainwright Global Investment Conference
-
Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting
-
Otonomy Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
Otonomy to Report First Quarter 2022 Financial Results and Provide Corporate Update
-
Otonomy Reports Positive Top-Line Results from Phase 2a Clinical Trial of OTO-413 in Patients with Hearing Loss
-
Otonomy to Host Virtual Investor R&D Event on March 22, 2022
-
Otonomy Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
-
Otonomy to Participate in Two Upcoming Investor Conferences
-
Otonomy to Host Virtual Investor R&D Event on March 22, 2022
-
Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus
-
Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
-
Otonomy Announces OTO-413 Presentations at American Auditory Society Annual Meeting
-
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
-
Otonomy Reports Corporate and Product Pipeline Update
-
Otonomy to Participate in the H.C. Wainwright BioConnect Conference
-
Otonomy to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
-
Otonomy Reports Third Quarter 2021 Financial Results and Provides Corporate Update
-
Otonomy to Report Third Quarter 2021 Financial Results and Provide Corporate Update
-
Otonomy Announces Multiple Presentations at Neuroscience 2021 Meeting
-
Otonomy Announces Publication of Phase 1/2 Trial Results Showing Tinnitus Improvement in Patients Receiving OTO-313
-
Otonomy Announces Presentation of OTO-413 Clinical Results at AAO-HNS Annual Meeting
-
Otonomy to Participate in Two Upcoming Investor Conferences
-
Otonomy Appoints Jill Broadfoot to Board of Directors
-
Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update
-
Otonomy to Report Second Quarter 2021 Financial Results and Provide Corporate Update
-
Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for OTO-413 in Hearing Loss
-
Otonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting
-
Otonomy Reports First Quarter 2021 Financial Results and Provides Corporate Update
-
Otonomy to Report First Quarter 2021 Financial Results and Provide Corporate Update
-
Otonomy and AGTC to Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting
-
Otonomy Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Otonomy Announces Pricing of $30.1 Million Public Offering
-
Otonomy Announces Proposed Public Offering
-
Otonomy to Present at the Needham Virtual Healthcare Conference
-
Otonomy Announces Presentation of OTO-313 Clinical Results at American Neurotology Society Annual Meeting
-
Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus
-
Otonomy to Participate in Three Upcoming Investor Conferences
-
Otonomy Announces Top-Line Results for the Phase 3 Clinical Trial of OTIVIDEX® in Patients with Ménière's Disease
-
Otonomy Announces Multiple Presentations at Association for Research in Otolaryngology Annual Meeting
-
Otonomy Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
-
Otonomy to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update
-
Otonomy to Participate in the H.C. Wainwright BioConnect 2021 Virtual Conference
-
Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-413 in Patients with Hearing Loss
Back to OTIC Stock Lookup
